Treat with XGEVA^®

XGEVA^® (denosumab): SUBCUTANEOUS INJECTION FOR THE PREVENTION OF SKELETAL-RELATED EVENTS (SREs) ^{[SmPC, p. 2]}

XGEVA^® is administered as a simple, fixed dose, subcutaneous injection every four weeks in adults with bone metastases from solid tumours. XGEVA^® should be administered under the responsibility of a healthcare professional.^{[SmPC, p. 2]}